Mercaptopurine 50 mg

DRUG2 trials

Sponsors

Mylan Pharmaceuticals Inc, Institute of Hematology & Blood Diseases Hospital, China

Conditions

HealthyPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Phase 1

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

CompletedNCT00648336

Mylan Pharmaceuticals IncHealthy

Start: 2003-11-30End: 2003-12-31Updated: 2024-04-24

Phase 2

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11